drugset
drugset / Trial / NCT00746590

Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

NCT00746590 ↗

Phase 2 Terminated 1 enrolled BTG International Inc.
NaSingle-groupOpen-labelTreatment

Summary

This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix in subjects with advanced hepatocellular carcinoma. Prolarix is a chemotherapy comprised of tretazicar as prodrug and caricotamide as co-substrate for the endogenous enzyme, NQO2.

Timeline

Start
2008-09
Primary completion
2009-06
Completion
2009-08

Outcome

Outcome not reported

Stopped (Enrollment): “Study terminated prematurely by sponsor for business reason. One patient was enrolled.”

Drugs

EvaluationDrugModalityDoseRoute
Subject caricotamide Small molecule 200 mg/m2 Intravenous
Subject tretazicar Small molecule 26.6 mg/m2 Intravenous

Indications

hepatocellular carcinoma